(April 1, 2014) Ovarian Cancer Research Fund is now accepting Letters of Intent for its three research grant programs. Letters of Intent must be submitted by May 6, 2014 at 5:00pm ET.
Related Topics
Global Ovarian Cancer Research Consortium Awards Inaugural AI Accelerator Grant with Microsoft’s AI for Good Lab
$1 million global research award, plus an additional $1 million in compute support, advances AI-driven efforts to personalize ovarian cancer care The Global Ovarian Cancer Research Consortium today awarded its inaugural AI Accelerator Grant to an international team of researchers to examine whether artificial intelligence (AI) can improve how survival and treatment response are predicted … Continued
FDA Approves First Ovarian Cancer Immunotherapy for PD-L1–Positive Platinum-Resistant Disease
The U.S. Food and Drug Administration (FDA) has approved the first immunotherapy regimen shown to extend survival in a subset of ovarian cancer patients. The FDA authorized Keytruda (pembrolizumab), made by Merck, in combination with chemotherapy, for PD-L1–positive, platinum-resistant epithelial ovarian, fallopian tube, and primary peritoneal cancers. Keytruda plus weekly Taxol (paclitaxel), with or without … Continued
The Overview: January 2026
Ovarian Cancer Research Alliance (OCRA) has announced a collaboration with OPERATION WIPE OUT, an initiative that has demonstrated meaningful success reducing cervical cancer risk in Alabama through prevention-focused education and access to care. Drawing on this proven public-health framework, OCRA will adapt and expand the model nationwide—bringing practical, evidence-based cervical cancer prevention strategies to communities … Continued